| Nov 6 |
Elevation Oncology GAAP EPS of -$0.22 misses by $0.02
|
| Nov 6 |
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
|
| Oct 10 |
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
|
| Oct 9 |
Empery Asset Management's Strategic Acquisition in Elevation Oncology
|
| Sep 23 |
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
|
| Sep 3 |
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 7 |
Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours
|
| Aug 6 |
Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results
|
| Aug 6 |
Elevation Oncology GAAP EPS of -$0.18
|
| Aug 6 |
Elevation Oncology falls after early-stage data for lead cancer drug
|
